Viewing nowCombinationHughliamex XR Tablets 50/500 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 202300602 · Approved 2023.02.17 · Insurance code 670609080
Improvement of glycemic control in patients with type 2 diabetes
This medication is designed to assist patients with type 2 diabetes in controlling blood sugar levels when used in conjunction with diet and exercise. The combined action of sitagliptin and metformin helps effectively improve blood sugar levels and supports healthy blood sugar management for patients. Therefore, this medication is used for patients with type 2 diabetes who have difficulties in managing their blood sugar.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. Patients previously taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.
This medication consists of two components, each used for the treatment of diabetes. The first component helps in blood sugar control; however, serious allergic reactions may occur in some patients. These reactions can appear within the first three months after starting the medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a healthcare professional. Additionally, pancreatitis, an inflammation of the pancreas, can occur rarely, so prompt reporting to healthcare professionals is needed if symptoms such as abdominal pain, nausea, or vomiting arise. The second component is not administered to patients with impaired kidney function or those with certain health conditions such as dehydration, severe infections, or heart problems. Moreover, if iodinated contrast is used for radiological examinations, the medication should be temporarily discontinued and only restarted after confirming normal kidney function. This medication is not recommended for use in pregnant or breastfeeding women, nor in children under 18 years of age. During treatment, symptoms of hypoglycemia may occur, particularly when used in combination with other blood sugar-lowering agents or insulin, so blood sugar levels should be monitored regularly and addressed immediately if symptoms arise. This medication may affect liver and kidney function, so regular blood tests and kidney function evaluations are required. Older adults particularly need to be cautious as kidney function may decline more easily. Additionally, refrain from alcohol consumption during treatment, and temporarily discontinue use before and after acute illness or surgery. Rarely, joint pain or skin diseases may occur; report any unusual symptoms to a healthcare professional. Finally, this medication may interact with other drugs, so inform your healthcare professional of any other medications you are taking.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly closed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication and prevent degradation.
Pale blue, bilaterally convex, oval-shaped extended-release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.